• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Orbimed Advisors Llc sold $138,193 worth of shares (230,321 units at $0.60) (SEC Form 4)

    12/26/24 4:34:10 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PASG alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ORBIMED ADVISORS LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Passage BIO, Inc. [ PASG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/20/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/20/2024 S 230,321 D $0.6 7,404,869 I See footnotes(1)(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    ORBIMED ADVISORS LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    OrbiMed Capital GP VII LLC

    (Last) (First) (Middle)
    601 LEXINGTON AVENUE
    54TH FLOOR

    (Street)
    NEW YORK NY 10022

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.
    2. Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
    /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC 12/26/2024
    /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC 12/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PASG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PASG

    DatePrice TargetRatingAnalyst
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    9/3/2024$7.00Buy
    Rodman & Renshaw
    3/8/2022Overweight → Neutral
    JP Morgan
    3/4/2022$29.00 → $24.00Outperform
    Raymond James
    1/19/2022$29.00 → $6.00Buy → Neutral
    Goldman
    7/1/2021$29.00Outperform
    Raymond James
    More analyst ratings

    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc sold $78,731 worth of shares (235,572 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/24/25 5:38:49 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $49,704 worth of shares (149,054 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/17/25 6:10:47 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Borthwick Kathleen

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      3/18/25 5:12:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

      Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp

      11/13/24 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Welcomes Tom Kassberg to Board of Directors

      PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission

      9/10/24 7:52:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

      Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202

      8/7/23 7:15:54 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Passage Bio Inc.

      SCHEDULE 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      4/25/25 7:48:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Passage Bio Inc.

      DEFA14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:01:31 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Passage Bio Inc.

      DEF 14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:00:29 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Passage Bio Inc.

      SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 7:06:55 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Passage Bio Inc.

      SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 5:15:23 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Financials

    Live finance-specific insights

    See more
    • Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

      Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET

      12/20/23 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

      Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET

      8/7/23 7:00:12 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

      Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW

      3/6/23 7:00:41 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush resumed coverage on Passage BIO with a new price target

      Wedbush resumed coverage of Passage BIO with a rating of Outperform and set a new price target of $4.00 from $3.00 previously

      11/29/24 7:25:55 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Passage BIO with a new price target

      Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00

      9/3/24 8:12:19 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio downgraded by JP Morgan

      JP Morgan downgraded Passage Bio from Overweight to Neutral

      3/8/22 5:15:06 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $241,038 worth of shares (373,645 units at $0.65) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      12/31/24 4:05:36 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $146,665 worth of shares (259,998 units at $0.56) and bought $137,855 worth of shares (196,355 units at $0.70) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      11/27/24 6:11:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

      Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative d

      3/4/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio to Participate in Upcoming Investor Conferences

      PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink Global Biopharma Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 12, 2025Presentation Time: 8:00 a.m. ETLocation: Miami, FL A live web

      2/26/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

      PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Completed process development and scale-up of a high-productivity, suspension-based manufacturing process for PBFT02 Extended cash runway into 1Q 2027 by moving to outsourc

      1/10/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care